Cardiotoxicity of Molecularly Targeted Agents

Author(s): Nadia Hedhli, Kerry S. Russell

Journal Name: Current Cardiology Reviews

Volume 7 , Issue 4 , 2011

Become EABM
Become Reviewer


Cardiac toxicity of molecularly targeted cancer agents is increasingly recognized as a significant side effect of chemotherapy. These new potent therapies may not only affect the survival of cancer cells, but have the potential to adversely impact normal cardiac and vascular function. Unraveling the mechanisms by which these therapies affect the heart and vasculature is crucial for improving drug design and finding alternative therapies to protect patients predisposed to cardiovascular disease. In this review, we summarize the classification and side effects of currently approved molecularly targeted chemotherapeutics.

Keywords: Cardiac toxicity, chemotherapy, cardiomyopathy, tyrosine kinases, proteasome inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [221 - 233]
Pages: 13
DOI: 10.2174/157340311799960636
Price: $65

Article Metrics

PDF: 13